Cargando…

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy

Purpose: To compare the efficacy and safety of computed tomography (CT)–guided (125)I seed implantation with second-line chemotherapy in treatment of oligorecurrence non–small cell lung cancer after failure of first-line chemotherapy. Methods: Data of oligorecurrence non–small cell lung cancer patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hao, Lu, Jian, Zheng, Xiao-Ting, Zha, Jun-Hao, Jing, Wen-Dong, Wang, Yong, Zhu, Guang-Yu, Zeng, Chu-Hui, Chen, Lei, Guo, Jin-He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179670/ https://www.ncbi.nlm.nih.gov/pubmed/32373512 http://dx.doi.org/10.3389/fonc.2020.00470

Ejemplares similares

To evaluate the efficacy and safety of (125)I seed implantation in SCLC as second line therapy
por: Cheng, Guoli, et al.
Publicado: (2022)

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?
por: Liu, Bin, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer
por: Huo, Xiaodong, et al.
Publicado: (2017)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis
por: Chen, Zhong-Ke, et al.
Publicado: (2022)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Percutaneous transhepatic cholangial drainage combined with intra-tumoral iodine-125 seeds implantation and chemotherapy for locally progressive pancreatic head cancer with obstructive jaundice
por: Ji, Liqiu, et al.
Publicado: (2022)

Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy
por: Pujol, Jean-Louis, et al.
Publicado: (2018)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
por: Dixon, A. R., et al.
Publicado: (1992)

Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review
por: Yuan, Mingli, et al.
Publicado: (2023)

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
por: Vashist, Yogesh, et al.
Publicado: (2022)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
por: Dai, Hongbin, et al.
Publicado: (2023)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial
por: Taïeb, Julien, et al.
Publicado: (2023)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
por: Song, Zhengbo, et al.
Publicado: (2014)

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Computed tomography-guided iodine-125 radioactive seed implantation in small-cell lung cancer: A retrospective study
por: Li, Mengjie, et al.
Publicado: (2022)

Computed tomography-guided implantation of (125)I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results
por: Li, Jie, et al.
Publicado: (2017)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Yamamoto, Akinaru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tq8bds20i8hjaj8rqfjhjf7f6m